EGFR and neoplasm: Another strategy is to target tumor-specific driver mutations that have already occurred in precancerous stages, such as KRAS and EGFR mutations for lung cancer prevention.408–410 These tumor-specific antigens are likely to be more immunogenic with better responses, but clinical trials are required to verify their efficacy and safety.